Sarcopenia Pipeline Shows Robust Growth with 18+ Pharma Companies Developing Novel Therapies
• The sarcopenia market remains largely untapped with no approved drug therapies in major markets, despite significant unmet medical needs in an aging global population.
• DelveInsight reports 18+ pharmaceutical companies actively developing 20+ pipeline drugs for sarcopenia, with promising candidates including Biophytis' BIO101, TNF Pharmaceuticals' MYMD-1, and Epirium Bio's MF-300.
• Recent regulatory milestones include Fast Track Designation for Lipocine's LPCN1148 for sarcopenia in patients with decompensated cirrhosis, signaling increased recognition of sarcopenia as a distinct clinical condition.
Biophytis Reports Promising Results: BIO101 and GLP-1 Combination Restores Muscle Strength in Obesity
• New preclinical data shows that combining BIO101 with GLP-1 receptor agonists significantly improved mobility and grip strength in diet-induced obese mice, addressing a critical gap in obesity treatment.
• The combination therapy compensates for muscle contractility alterations induced by GLP-1 alone, potentially offering a solution for the 96% of obesity patients who experience muscle strength decline.
• Biophytis is advancing BIO101 to Phase 2 clinical trials for obesity, building on previous positive results from SARA-INT and Quinolia studies that demonstrated improved muscle function in human subjects.
Biophytis' BIO101 Shows Promising Phase II Results in Sarcopenia Treatment, Advancing to Phase III
• Biophytis SA has published positive Phase II SARA-INT clinical trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle, demonstrating clinically meaningful improvement in the 400-meter walk test.
• The drug candidate showed an excellent safety profile with no serious adverse events, with greater efficacy observed in high-risk populations including slow walkers and patients with sarcopenic obesity.
• As the most advanced company developing treatments for sarcopenia, which affects 121-194 million people worldwide, Biophytis is preparing for Phase III trials and accelerating partnership discussions with pharmaceutical companies in China and Asia.
Novavax Launches Clinical Trial for JN.1 Subvariant COVID-19 Vaccine
Novavax initiates a new clinical trial to evaluate the safety and immunogenicity of its JN.1 subvariant vaccine (NVX CoV2705) with Matrix-M adjuvant. The study will compare results with the previously authorized NVX-CoV2601 vaccine, marking a significant step in addressing emerging COVID-19 variants.
© Copyright 2025. All Rights Reserved by MedPath